[1]刘志南,管怀进.雷珠单抗和阿柏西普对年龄相关性黄斑变性患者外层视网膜管状结构的影响[J].眼科新进展,2019,39(10):952-955.[doi:10.13389/j.cnki.rao.2019.0217]
 LIU Zhi-Nan,GUAN Huai-Jin.Effects of ranibizumab and aflibercept on outer retinal tubulation of patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2019,39(10):952-955.[doi:10.13389/j.cnki.rao.2019.0217]
点击复制

雷珠单抗和阿柏西普对年龄相关性黄斑变性患者外层视网膜管状结构的影响/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年10期
页码:
952-955
栏目:
应用研究
出版日期:
2019-10-05

文章信息/Info

Title:
Effects of ranibizumab and aflibercept on outer retinal tubulation of patients with age-related macular degeneration
作者:
刘志南管怀进
226000 江苏省南通市,南通大学(刘志南);226000 江苏省南通市,南通大学附属医院眼科(管怀进)
Author(s):
LIU Zhi-NanGUAN Huai-Jin
Nantong University(LIU Zhi-Nan),Nantong 226000,Jiangsu Province,China;Department of Ophthalmology,the Affiliated Hospital of Nantong University(GUAN Huai-Jin),Nantong 226000,Jiangsu Province,China
关键词:
年龄相关性黄斑变性雷珠单抗阿柏西普外层视网膜管状结构
Keywords:
age-related macular degenerationranibizumabafliberceptouter retinal tubulation
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2019.0217
文献标志码:
A
摘要:
目的 分析雷珠单抗和阿柏西普对年龄相关性黄斑变性(age-related macular degeneration,AMD)患者外层视网膜管状结构(outer retinal tubulation,ORT)的影响。方法 收集2016年2月至2018年1月医院收治的110例(142眼)AMD患者的临床资料,按治疗方式分为雷珠单抗组(65例82眼)与阿柏西普组(45例60眼),均完成术后2 a随访,记录治疗前后两组患者视力、黄斑中心凹厚度(central foveal thickness,CFT)及ORT的变化。结果 基线、治疗后6个月两组治疗眼数比较差异均无统计学意义(均为P>0.05),治疗后12个月、24个月雷珠单抗组治疗眼数比例(86.59%、26.83%)均高于阿柏西普组(55.00%、0,均为P<0.05)。两组治疗后6个月、12个月、24个月最佳矫正视力均有不同程度上升[雷珠单抗组:77.18±10.21、74.24±12.46、73.36±10.71;阿柏西普组:75.45±13.56、75.71±14.74、72.65±11.99],均高于同组治疗前[59.15±13.92、59.21±14.01](均为P<0.05),但组间差异均无统计学意义(均为P>0.05)。两组治疗后6个月、12个月、24个月CRT[雷珠单抗组:(345.22±30.71)μm、(340.37±41.05)μm、(341.67±42.02)μm;阿柏西普组:(346.87±29.68)μm、(341.65±42.65)μm、(343.41±40.87)μm]均较治疗前[(389.57±58.65)μm、(388.67±57.54)μm]降低(均为P<0.05),但组间不同时间点比较差异均无统计学意义(均为P>0.05)。治疗后6个月、12个月、24个月两组ORT(雷珠单抗组:34.15%、46.34%、60.98%;阿柏西普组:40.00%、60.00%、68.33%)均较基线上升(18.29%、23.33%),但组间比较差异均无统计学意义(均为P>0.05)。结论 湿性AMD患者ORT患病率随时间的推移增加,抗VEGF药物治疗可改善患者视力及黄斑形态,但无法抑制ORT进展,必须重视鉴别ORT与视网膜下液及水肿,减少过度治疗。
Abstract:
Objective To analyze the effects of ranibizumab and aflibercept on outer retinal tubulation (ORT) of patients with age-related macular degeneration (AMD).Methods The clinical data of 110 patients (142 eyes) with AMD admitted to the hospital from February 2016 to January 2018 were collected.They were divided into ranibizumab group (65 patients,82 eyes) and aflibercept group (45 patients,60 eyes) according to treatment methods.All patients underwent postoperative follow-up for 2 year.The changes in visual acuity,central foveal thickness (CFT) and ORT in both groups were recorded before and after treatment.Results There was no significant difference in the number of treated eyes between the two groups at baseline and at 6 months after treatment (all P>0.05).The proportion of number of treated eyes in ranibizumab group at 12 months and 24 months after treatment was higher than that in aflibercept group [(86.59%,26.83%) vs.(55.00%,0)] (all P<0.05).The best corrected visual acuity at 6 months,12 months and 24 months after treatment was 77.18±10.21,74.24±12.46,73.36±10.71 in the ranibizumab group,and 75.45±13.56,75.71±14.74,72.65±11.99 in the aflibercept group,which were increased in both groups to different degrees,and the above data were higher than those before treatment in the same group [59.15±13.92,59.21±14.01] (all P<0.05),but there were no significant differences between the two groups (all P>0.05).The CRT at 6 months,12 months and 24 months after treatment was (345.22±30.71)μm,(340.37±41.05)μm,(341.67±42.02)μm in the ranibizumab group,and (346.87±29.68)μm,(341.65±42.65)μm,(343.41±40.87)μm in the aflibercept group,which was decreased in both groups compared with those before treatment [(389.57±58.65)μm,(388.67±57.54)μm] (all P<0.05),but there were no significant differences between the two groups at different time points (all P>0.05).The incidence of ORT in the two groups increased at 6 months,12 months and 24 months after treatment (Ranibizumab group:34.15%,46.34%,60.98%.Aflibercept group:40.00%,60.00%,68.33%) compared with those at baseline (18.29%,23.33%),but there were no significant differences between the two groups (all P>0.05).Conclusion The prevalence of ORT in patients with wet AMD increases over time.Anti-VEGF drug therapy can improve visual acuity and macular morphology,but cannot inhibit ORT progression.It is necessary to pay attention to the identification of ORT,subretinal fluid and edema in order to reduce over-treatment.

参考文献/References:

[1] SHU B J,LEI S H,CHEN Y,ZHU J L.Comparison of effects of ramizumab and Conbercept in the treatment of wet age-related macular degeneration[J].J Clin Med Pract,2018,22(17):93-95,98.
舒宝君,雷淑红,陈瑜,朱佳丽.雷珠单抗与康柏西普治疗湿性年龄相关性黄斑变性的效果比较[J].实用临床医药杂志,2018,22(17):93-95,98.
[2] LITTS K M,THOMAS A,HAMMACK K M,SLOAN K R,ZHANG Y H,FREUND B,et al.Quantitative analysis of outer retinal tubulation in age-related macular degeneration from spectral-domain Optical Coherence Tomography and Histology[J].Invest Ophthalmol Vis Sci,2016,57(6):2647-2656.
[3] DENG L H,TAN G,WU K,WANG S L.Comparison of single dose injection of Combercept and remizumab in treatment of exudative age-related macular degeneration[J].Med Sci J Cent South China,2018,46(6):657-659,666.
邓吕红,谭钢,吴恺,王水莲.康柏西普、雷珠单抗单次玻璃体注射治疗渗出型年龄相关性黄斑变性疗效比较[J].中南医学科学杂志,2018,46(6):657-659,666.
[4] CHEN M,XIANG B X,RUAN Y X,WANG Y L,CAI X J.Efficacy of intravitreal injection of ranibizumab in the treatment of patients with exudative age-related macular degeneration[J].Rec Adv Ophthalmol,2018,38(1):77-79,83.
陈明,项宝鑫,阮余霞,王永力,蔡小军.玻璃体内注射雷珠单抗对渗出型年龄相关性黄斑变性患者的疗效[J].眼科新进展,2018,38(1):77-79,83.
[5] SHEN Z S,CHEN M P.The contrast observation of the vitreous cavity injection of Combercept or Ranibizumab to treat wet age-related macular degeneration[J].Chin J Pract Ophthalmol,2017,35(6):563-566.
申战省,陈梦平.康柏西普与雷珠单抗治疗湿性年龄相关性黄斑变性对比观察[J].中国实用眼科杂志,2017,35(6):563-566.
[6] YAN P S,WAN G M,DONG Y,QIAN C,CHEN Y,LI F Z,et al.Analysis on the effect of Ranibizumab combined with photodynamic therapy in the treatment of age-related macular degeneration[J].Int Eye Sci,2017,17(5):933-936.
闫磐石,万光明,董一,钱诚,陈悦,李福祯,等.雷珠单抗联合光动力疗法对年龄相关性黄斑变性CNV的治疗效果[J].国际眼科杂志,2017,17(5):933-936.
[7] FEI Y,WANG H.Measurement of central foveal thickness in high myopia post-phacoemulsification using optical coherence tomography[J].Int Eye Sci,2017,17(8):1501-1503.
费芸,汪浩.应用OCT观察高度近视并发白内障患者超声乳化术后黄斑中心凹厚度变化[J].国际眼科杂志,2017,17(8):1501-1503.
[8] WANG X N,ZHAO J W,DU X H,WU Q.The change of central retinal thickness and subfoveal choroidal thickness in patient with central retinal artery occlusion during short-term treatment[J].Chin J Ocul Fundus Dis,2018,34(3):237-241.
王相宁,赵佳玮,杜新华,吴强.视网膜中央动脉阻塞患眼治疗前后黄斑中心凹视网膜和脉络膜厚度变化[J].中华眼底病杂志,2018,34(3):237-241.
[9] CHEN X L,SHI D P,XU H F,YING L.OCT characteristics and clinical significance of outer retinal tubular structure in the eyes of wet age-related macular degeneration[J].Rec Adv Ophthalmol,2014,34(10):940-942.
陈秀丽,石德鹏,徐海峰,应良.湿性年龄相关性黄斑变性眼中外层视网膜管状结构的OCT特征及其临床意义[J].眼科新进展,2014,34(10):940-942.
[10] TOTO L,BORRELLI E,MASTROPASQUA R,DI ANTONIO L,DORONZO E,CARPINETO P,et al.Association between outer retinal alterations and microvascular changes in intermediate stage age-related macular degeneration:an optical coherence tomography angiography study[J].Br J Ophthalmol,2017,101(6):774-779.
[11] LIU S.Research progress of anti-VEGF for the therapy in wet age-related macular degeneration[J].Chin J Experiment Ophthalmol,2018,36(12):962-966.
刘舒.抗血管内皮细胞生长因子药物治疗湿性年龄相关性黄斑变性研究现状[J].中华实验眼科杂志,2018,36(12):962-966.
[12] ENDERS P,SITNILSKA V,ALTAY L,SCHAUB F,MUETHER P S,FAUSER S.Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis[J].Ophthalmologica,2017,237(2):111-118.
[13] XUE K,OLDANI M,JOLLY J K,EDWARDS T L,GROPPE M,DOWNES S M,et al.Correlation of optical coherence tomography and autofluorescence in the outer retina and choroid of patients with choroideremia[J].Invest Opthalmol Vis Sci,2016,57(8):3674-3684.
[14] JAFFE G J,KAISER P K,THOMPSON D,GIBSON A,SAROJ N,VITTI R,et al.Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid[J].Ophthalmology,2016,123(9):1856-1864.
[15] HU J P,YANG H,LI G D,CHEN J,LI D L,CAI N,et al.Macular visual field changes after combined photodynamic therapy and intravitreal injection of ranibizumab for neovacular age-related macular degeneration[J].Rec Adv Ophthalmol,2015,35(11):1039-1043.
胡军平,杨华,李国栋,陈静,李冬莉,蔡宁,等.光动力疗法联合玻璃体内注射雷珠单抗治疗湿性年龄相关性黄斑变性后黄斑区中心视野的改变[J].眼科新进展,2015,35(11):1039-1043.
[16] HARIRI A,NITTALA M G,SADDA S V R.Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration[J].Ophthalmology,2015,122(2):407-413.
[17] ZHAO L,HONG H,XIE G L,WANG Y L.Effects of intravitreal injection of ranibizumab on choroidal thickness and blood flow of posterior ciliary artery in patients with wet age-related macular degeneration[J].Rec Adv Ophthalmol,2016,36(8):745-747.
赵露,洪慧,谢国丽,王艳玲.玻璃体内注射雷珠单抗对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].眼科新进展,2016,36(8):745-747.
[18] ESPINA M,ARCINUE C A,MA F,CAMACHO N,BARTESELLI G,MENDOZA N,et al.Outer retinal tubulations response to anti-VEGF treatment[J].Br J Ophthalmol,2015,100(6):819-823.
[19] WEI Y L,RAN L J,LIAO H X,CHEN S Q,YE J.Effects of conbercept and ranibizumab on serum levels of CRP,VEGF,intraocular pressure and visual acuity in patients with age-related macular degeneration[J].Prog Mod Biomed,2018,18(8):1515-1518.
魏艳丽,冉莉君,廖洪霞,陈少琼,叶剑.康柏西普与雷珠单抗对年龄相关性黄斑变性患者血清CRP、VEGF、眼压及视力的影响[J].现代生物医学进展,2018,18(8):1515-1518.

相似文献/References:

[1]范姜砾 王雨生 张鹏.湿性年龄相关性黄斑变性患者血浆中相关抗氧化酶水平测定[J].眼科新进展,2012,32(5):000.
[2]王毅 李罗翔 李娟 曾庆华.ApoE基因缺失小鼠视网膜及Bruch膜组织形态观察[J].眼科新进展,2013,33(1):000.
[3]徐新荣 仲路 黄冰林 魏源华 周欣 王玲 王富强.年龄相关性黄斑变性血浆蛋白质组学初步研究[J].眼科新进展,2013,33(2):000.
[4]党亚龙 陈彬川 穆雅林 赵满丽 朱豫.i-MP对产生2型脉络膜新生血管的年龄相关性黄斑变性患者视力及黄斑厚度的影响[J].眼科新进展,2013,33(2):000.
[5]王毅 李罗翔 李进辉 李娟 曾庆华.血脂异常ApoE基因缺失小鼠视网膜色素上皮细胞胞浆内黑色素和脂褐素的改变[J].眼科新进展,2013,33(7):000.
[6]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[7]陆秉文 吴星伟.光动力疗法治疗年龄相关性黄斑变性的研究进展[J].眼科新进展,2013,33(4):000.
[8]栾兰 姚勇.湿性年龄相关性黄斑变性的治疗进展[J].眼科新进展,2013,33(4):000.
[9]李姣 王兴荣 崔彦 刘正峰 王影 李洋.雷珠单抗选择性体外抑制睫状体恶性黑色素瘤[J].眼科新进展,2013,33(11):000.
[10]胡艳红 祁明信 郭娜 陈胜 柯发杰.渗出型年龄相关性黄斑变性患者外周血CCR3的表达[J].眼科新进展,2013,33(11):000.
[11]胡军平,杨华,李国栋,等.光动力疗法联合玻璃体内注射雷珠单抗治疗湿性年龄相关性黄斑变性后黄斑区中心视野的改变[J].眼科新进展,2015,35(11):1039.[doi:10.13389/j.cnki.rao.2015.0284]
 HU Jun-Ping,YANG Hua,LI Guo-Dong,et al.Macular visual field changes after combined photodynamic therapy and intravitreal injection of ranibizumab for neovacular age-related macular degeneration[J].Recent Advances in Ophthalmology,2015,35(10):1039.[doi:10.13389/j.cnki.rao.2015.0284]
[12]郑燕林,彭晓丽,陈廷,等.Lucentis治疗黄斑脉络膜新生血管1年的临床疗效观察[J].眼科新进展,2016,36(4):348.[doi:10.13389/j.cnki.rao.2016.0094]
 ZHENG Yan-Lin,PENG Xiao-Li,CHEN Ting,et al.Clinical effects of Lucentis in treatment of macular choroid neovascularization for l year[J].Recent Advances in Ophthalmology,2016,36(10):348.[doi:10.13389/j.cnki.rao.2016.0094]
[13]赵露,洪慧,谢国丽,等.玻璃体内注射雷珠单抗对湿性年龄相关性黄斑变性患者脉络膜厚度及睫状后动脉血流的影响[J].眼科新进展,2016,36(8):745.[doi:10.13389/j.cnki.rao.2016.0198]
 ZHANG Lu,HONG Hui,XIE Guo-Li,et al.Effects of intravitreal ranibizumab injection on subfoveal choroidal thickness and posterior ciliary artery hemodynamics in patients with wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(10):745.[doi:10.13389/j.cnki.rao.2016.0198]
[14]张雨晴,邵毅,葛倩敏,等.玻璃体内注射雷珠单抗对年龄相关性黄斑变性患者眼表的影响[J].眼科新进展,2020,40(3):235.[doi:10.13389/j.cnki.rao.2020.0055]
 ZHANG Yuqing,SHAO Yi,GE Qianmin,et al.Clinical study of ocular surface damage caused by intravitreal injection of Ranibizumab in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2020,40(10):235.[doi:10.13389/j.cnki.rao.2020.0055]
[15]胡伟男,蔡文婷,邹爱琪,等.精氨酸-甘氨酸-天冬氨酸修饰的星型高分子负载雷珠单抗对脉络膜新生血管靶向治疗作用[J].眼科新进展,2021,41(2):130.[doi:10.13389/j.cnki.rao.2021.0027]
 HU Weinan,CAI Wenting,ZOU Aiqi,et al.Targeted therapy effect of arginine-glycine-aspartate modified star polymer loaded ranibizumab on choroidal neovascularization[J].Recent Advances in Ophthalmology,2021,41(10):130.[doi:10.13389/j.cnki.rao.2021.0027]
[16]臧涵怡,包欣,赵伟.雷珠单抗1+PRN和3+PRN治疗湿性年龄相关性黄斑变性的对比研究[J].眼科新进展,2021,41(11):1072.[doi:10.13389/j.cnki.rao.2021.0225]
 ZANG Hanyi,BAO Xin,ZHAO Wei.Efficacy of ranibizumab 1+PRN and 3+PRN in the treatment of wet age-related macular degeneration[J].Recent Advances in Ophthalmology,2021,41(10):1072.[doi:10.13389/j.cnki.rao.2021.0225]
[17]赵文,赵斐,李敏,等.CFH基因多态性与玻璃体液VEGF对年龄相关性黄斑变性患者抗VEGF疗效影响的交互作用[J].眼科新进展,2022,42(12):962.[doi:10.13389/j.cnki.rao.2022.0197]
 ZHAO Wen,ZHAO Fei,LI Min,et al.Interaction between complement factor H gene polymorphism and vascular endothelial growth factor in vitreous humor on anti-vascular endothelial growth factor efficacy in patients with age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(10):962.[doi:10.13389/j.cnki.rao.2022.0197]

更新日期/Last Update: 2019-10-12